PFE - Bicycle Therapeutics Files For U.S. IPO
Quick Take
Bicycle Therapeutics (BCYC) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing antibody-like therapeutics for the treatment of underserved diseases.
BCYC has developed several commercial collaborations outside its core area of focus and expects initial results from Phase I/IIa trials for its lead candidate in the second half of 2019.
Company & Technology
Cambridge, UK-based Bicycle Therapeutics was founded in 2009 to discover novel therapeutics that combine the pharmacology usually associated with a large and complex